Instructions for Biosafety Application

Office of Research and Innovation 376 University Hall Wright State University Dayton, OH 45435 (937) 775-2425

Please use the attached application for requesting a review and approval of activities involving biohazardous agents by the Wright State University Institutional Biosafety Committee (IBC). This application should be used for all activities including research, teaching, and testing. The IBC requests the information in accordance with its charge. This information is required by the Occupational Safety and Health Administration's Occupational Exposure to Hazardous Chemicals in Laboratories Standard, its Blood-Borne Pathogen Standard and/or the NIH Guidelines for Research Involving Recombinant DNA (rDNA) Molecules.

The application rules and procedures are as follows:

- Use the "Save As" function to save document.
- Please be thorough and complete all sections please type.
 - o Incomplete applications will be returned without review.
 - o Hand written applications will be returned without review.
- If you need more space, attach additional sheets.
- Obtain necessary signatures.
- Allow the Biosafety Officer at least one week prior to the submission deadline for review of application.
- Submission deadlines will be strictly enforced. For a complete listing of these dates, please refer to the Office of Research and Innovation's website at
 <u>Biosafety Meeting and Deadline Dates</u> or contact the IBC Compliance Coordinator as listed below.

Submit completed application to:

IBC Compliance Coordinator Office of Research and Innovation 376 University Hall Wright State University Dayton, OH 45435 937-775-2425/3781 (voice/fax) amanda.karper@wright.edu

For additional information or assistance in completing this form, please contact the Department of Environmental Health and Safety at 937-775-2215/3761 (voice/fax).

Note: The information provided may become publicly available under Ohio's Open Records Act.



Biosafety ApplicationWright State University

| For RSP use only: | |
|-------------------------|--------|
| Biosafety Protocol No.: | |
| Date Received: | |
| | 100000 |

| Research and Sponsored Program | | | | |
|--|-------------------------|---|--|--|
| This application contains proprietary/confidential information (Please attach a justification statement and any relevant documentation). | | | | |
| Project Title (limit 81 characters, inclu | ding spaces and punctua | tion): | | |
| Principal Investigator Section | | | | |
| PI Name/Title: | | | | |
| Department: | | | | |
| Phone: | En | nail: | | |
| described in this application. The | | the safe conduct of work with the agents oplication is accurate and complete. | | |
| Laboratory Personnel Section (a The undersigned individual(s) are | | • | | |
| 1. Name: | Role: | Email: | | |
| Lab Chem Safety: | Biosafety train | ning: | | |
| Signature: | Haz Com: | BBP: | | |
| | | | | |
| 2. Name: | Role: | Email: | | |
| Lab Chemical Safety: | Biosafety train | | | |
| Signature: | Haz Com: | BBP: | | |
| 3. Name: | Role: | Email: | | |
| Lab Chemical Safety: | Biosafety train | | | |
| Signature: | Haz Com: | BBP: | | |
| | 1 | | | |
| 4. Name: | Role: | Email: | | |
| Lab Chemical Safety: | Biosafety training: | | | |
| Signature: | Haz Com: BBP: | | | |
| | | | | |
| 5. Name: | Role: | Email: | | |
| Lab Chemical Safety: | | Biosafety training: | | |
| Signature: | Haz Com: | BBP: | | |

| 6. Name: | Role: | Email: | |
|--------------------------------------|----------------------------|-------------|--|
| Lab Chemical Safety: | Biosafety training | | |
| Signature: | Haz Com: | BBP: | |
| | | | |
| 7. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | ; | |
| Signature: | Haz Com: | BBP: | |
| | | | |
| 8. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | : | |
| Signature: | Haz Com: | BBP: | |
| | | | |
| 9. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | · | |
| Signature: | Haz Com: | BBP: | |
| | | | |
| 10. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | : | |
| Signature: | Haz Com: | BBP: | |
| | | · | |
| 11. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | ; | |
| Signature: | Haz Com: | BBP: | |
| | | | |
| 12. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | ; | |
| Signature: | Haz Com: | BBP: | |
| | | | |
| 13. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | · | |
| Signature: | Haz Com: | BBP: | |
| | | · | |
| 14. Name: | Role: | Email: | |
| Lab Chemical Safety: | Biosafety training | • | |
| Signature: | Haz Com: | BBP: | |
| | · | <u>,</u> | |
| Biosafety Officer Section | | | |
| I have reviewed this application and | d found it be suitable for | IBC review: | |
| | | | |
| | | | |
| /0: CD | ionafaty Office | | |
| (Signature of B | iosafety Officer) | | |

| 1. | Project Location(s) (Room/Bldg): |
|----|---|
| 2. | Animal Use? |
| 4. | Select Agent Use? Yes No If Yes, STOP here and contact the Institutional Biosafety Officer. |
| 5. | Which of the following biological agents will be used? (check all that apply) |
| | ☐ Recombinant DNA (rDNA) ☐ Nonrecombinant DNA/RNA or Prions ☐ Biological Toxins ☐ Tissue or Cell Culture ☐ Human or Non-Human Primate Tissue ☐ Microorganisms |
| 6. | What level of biocontainment will be used? BSL-1 BSL-2 BSL-2+ BSL-3 |
| 7. | Recombinant DNA Section (Not Applicable, next section): a. Are your activities exempt? Yes No Refer to: http://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf (note exceptions) If Yes, list exemption category: If category is III-F-6, list system: b. Will you express any drug or immunological resistance genes? Yes No |
| | Refer to: http://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf for complete details. The descriptions in parentheses are provided only as a guide. Section III-A (Transfer of drug resistance genes into microorganisms that are not known to acquire the trait naturally) Section III-B (Cloning of toxins with LD ₅₀ < 100 ng/kg body weight) Section III-C (Transfer of rDNA, DNA, or RNA derived from rDNA into human subjects) Section III-D (rDNA from Risk Group 2, 3, 4, or restricted agents as vector systems; Infectious or defective DNA or RNA viruses; Whole animals and plants; Large volumes) Section III-E (rDNA involving < 2/3 of the genome of any eukaryotic virus in the |
| | Section III-C (Transfer of rDNA, DNA, or RNA derived from rDNA into human subjects) Section III-D (rDNA from Risk Group 2, 3, 4, or restricted agents as vector systems; Infectious or defective DNA or RNA viruses; Whole animals and plant Large volumes) |

- 7. Recombinant DNA Section (continued):
 - g. Complete table below using one column per construct (deletion or mutation series of a gene may be listed in one column; use additional sheet if necessary).

| , | Construct 1 | Construct 2 | Construct 3 | Construct 4 | Construct 5 | Example |
|---|-------------|-------------|-------------|-------------|-------------|---|
| Name and Provider of Gene | | | | | | Example: green fluorescent protein from Clontech |
| Gene Function | | | | | | Example: marker |
| Vector Name | | | | | | Example: pKH-WSU24 |
| Vector Type / Species and Strain | | | | | | Example: Viral / Adenovirus serotype 5 |
| Expression control elements (promoters, enhancers, etc) | | | | | | Example: CMV promoter |
| Conc/titer of rDNA (i.p./ml) | | | | | | Example: 1 X 10 ⁸ to 1 X10 ¹² infectious particles/ml |
| Host and Strain, if applicable | | | | | | Example: E. coli, Sure TM , Mouse heart cells, in vivo |
| Largest Production Volume of Host | | | | | | Example: 1 liter |
| Host Range (including any genetic alterations to host range) | | | | | | Example: amphotropic, broad mammalian host range |
| Is recombinant made in your lab? If not, where? | | | | | | Example: Vanderbilt Univ. Gene Therapy Center |
| If vector is a genome, what % has been deleted or substituted? | | | | | | Example: 10% |

| 0 | N.T. | 1' | | | |
|----|---|--|--|--|--|
| 8. | Nonrecombinant or Synthetic DNA/RNA; Prions Section (Not Applicable , next section) | | | | |
| | a. | . Are you handling DNA or RNA from pathogenic microorganisms? Yes No | | | |
| | | If Yes, list: | | | |
| | b. | Are you handling oncogenic DNA sequences? Yes No | | | |
| | | If Yes, list: | | | |
| | c. | Are you handling DNA containing drug resistance genes? Yes No | | | |
| | | If Yes, list: | | | |
| | d. | Are you working with any prions? Yes No | | | |
| | | If Yes, complete the following table (use additional sheet if necessary): | | | |
| | | Pathogenic PrP | | | |
| | | Name of Prion Isoform Disease Natural Host | | | |
| | | Tvaine of Friori | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | e. | If Yes to ques. 8a-d, please list the provider(s) of the agents: | | | |
| | | | | | |
| | | | | | |
| | f. | If Yes to ques. 8a-d, please explain what safety steps you will take to avoid percutaneous and | | | |
| | | mucous membrane exposure of laboratory personnel and contamination of the environment | | | |
| | | | | | |
| | | | | | |
| | g. | If Yes to ques. 8a-d, what types of sharps will be used and how will they be disposed of? | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| 9. | | oxins Section (Not Applicable, next section): | | | |
| | a. | Are you handling toxins of biological origin? Yes No | | | |
| | | If Yes, list the name and provider of toxin(s): | | | |
| | | • | | | |
| | b. | In what form is the toxin(s) received? | | | |
| | c. | Will you reconstitute the toxin(s)? Yes No | | | |
| | | If Yes, describe: | | | |
| | d. | What is the highest concentration with which you will work or possess? | | | |
| | | | | | |
| | e. | What is the LD ₅₀ expressed in ng per kg body weight? | | | |
| | | | | | |
| | f. | Do you agree to comply with Appendix I of BMBL, which includes maintaining an inventory | | | |
| | | system, secure storage, and proper use of primary and secondary containment? | | | |
| | | See: https://www.cdc.gov/labs/BMBL.html Yes No | | | |

| 10. Tissue and Cell Cultu | re Section (Not A | Applicable [], 1 | next section): | | |
|--|-------------------|---------------------------|----------------|-------------------------|-----|
| | | Catalog | | Infectious | |
| Tissues/Cells | Provider | Number | Туре | Agents? (List) | BSL |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Use additional sheet, if no | ecessary | | | | |
| 11. Human or Non-human Primate Tissue Section (Not Applicable ☐, next section):a. Are you handling human or nonhuman primate tissue or fluids? ☐ Yes ☐ No If Yes, list (include species): | | | | | |
| b. What is the source and provider of the tissue(s)? | | | | | |
| c. Are the tissues known or suspected to be infected? Yes No If Yes, describe: | | | | | |
| d. Has your staff taken the blood borne pathogen program? Yes No If Yes, list names and dates: | | | | | |
| | | | | | |
| | | | | | |
| 12. Microorganism Section (Not Applicable, next section): | | | | | |
| a. Which category o | f microorganism | is being used? (| check all that | apply) | |
| ☐ Bacteria ☐ Archaea ☐ Virus | | Fungi Unicellular Alga | e | Protozoa Parasitic Worn | ns |

| | PI Name: _ | | |
|--|--|------------|--------------|
| 12. Microorganism Section (Continued): | | | |
| b. List each agent and its risk group, biosafety level, and provider (use additional sheet if necessary). Refer to https://my.absa.org/Riskgroups for details . | | | |
| Agent (genus, species, strain) | Risk Group | BSL | Provider |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| c. Are you producing or receiving vector virus? Yes No If yes, please describe any safety features that prevent the generation of recombinant virus and methods of safety testing that have been performed or will be conducted: | | | |
| | | | |
| 13. Safety Equipment Section | | | |
| Biological Safety Cabinet(s)? | Sterilizer Avail | lable? | Yes No |
| Cabinet #1 Type: | Type: | | |
| Location: | · | 5): | |
| Certification Date: Hand w | | sink avail | able? Yes No |
| Cabinet #2 Type: Location: | Location: Location(s): | | |
| Certification Date: | Personal Protective Equipment Used (list): | | |
| Cabinet #3 Type: | | | |
| Location: Certification Date: | | | |
| Setundadii Date. | | | |

| 14. Sa | fety Procedures Section |
|--------|---|
| a. | Will you work with biohazardous agents in any of the following aerosol-producing devices or procedures? Yes No (check all that apply) |
| | Aspirators Intranasal Inoculation Pressurized Vessels Blenders Large Volumes (≥10L) Shakers Centrifuges Necropsy Sonicators Homogenizers Pipetting Infectious Liquids Vortexers Other, please list: Other |
| | If Yes to any of the above, describe how you will contain the aerosol: |
| | If using sonicator, how will you provide hearing protection to all workers in the area? |
| b. | Do you concentrate the biohazardous agents? Yes No (check all that apply) Centrifugation Filtration Precipitation Other, please list: If Yes, which agent is being concentrated? |
| C. | Are you using a vacuum supply with the biohazardous agents? |
| d. | At any time during the procedures, will biohazardous agents be moved from a higher safety level to a lower one? Yes No |
| | If Yes, provide a justification and describe method of inactivation for this step: |
| e. | How do you generally inactivate the biohazardous agents described in this application? |
| f. | How do you disinfect surfaces in the laboratory? |
| | |
| 15. W | aste Generation Section |
| a. | Are you generating biological waste? Yes No Refer to EHS Exposure Control Plan for definitions. If Yes, specify type: |
| b. | Are you generating mixed waste? Yes No (check all that apply) |
| | ☐ Biological and Chemical Hazard ☐ Biological and Radiological Hazard ☐ Biological, Chemical, and Radiological Hazard |
| c. | Have you notified the Department of Environmental Health and Safety? Yes No |

| | PI Name: |
|--------|--|
| 16. Tr | ransport and Transfer Section |
| a. | Will you transport or transfer biohazardous agents? Yes No |
| | [Transport refers to packaging and shipping these agents by air, land, or sea via airplanes, motor vehicles, boats, or other means. Transfer refers to exchanging these agents between laboratories, generally between rooms or buildings within a facility or institute.] |
| | If Yes, describe agents and method of transport or transfer: |
| b. | If transporting agents in my personal vehicle, I accept responsibility for the personal liability I may incur in the event of an accident. Yes No N/A |
| c. | The transport and transfer of biological agents is governed by the Center for Disease Control (CDC) and the Federal Government. Do you agree to comply with the CDC and Federal regulations? Yes No N/A Refer to BLBM Appendix C |
| | Refer to https://hazmat.dot.gov/ for Federal Hazardous Materials Transportation Law. Refer to "Transporting Infectious Substances Safely" document. |

| 17. Assurances S | ection. Please answer Yes or No. |
|------------------|---|
| □Yes □No | If required, Material Transfer Agreements (MTAs) will be secured for the above described biohazardous agents transferred to or from Wright State University. MTAs are administered through the Office of Technology Transfer and Development. |
| Yes No | The Principal Investigator is trained for the proposed studies. |
| ☐Yes ☐No | All personnel will receive the appropriate training in regard to safety practices and protective equipment for this work. |
| Yes No | Written experimental procedures will be maintained in the laboratory. |
| □Yes □No | Laboratory procedures will be in compliance with the <i>University Chemical Hygiene Plan</i> , the <i>Institutional Biosafety Manual</i> , the OSHA Laboratory Safety Standard, other appropriate OSHA Standards, and the Ohio Revised Code. |
| Yes No | Biological safety cabinets (BSCs) shall be maintained in sound working condition at all times and shall be certified annually and after each move or maintenance procedure. Laboratory personnel are aware of the operational limits of BSCs. |
| ☐Yes ☐No | Chemical fume hoods shall never be used to contain biohazards. |
| ☐Yes ☐No | No employee or researcher will be asked to intentionally consume or otherwise be exposed to a biological agent as part of a research protocol. |
| □Yes □No | All biological waste will be properly disposed in compliance with Infectious Waste Management Guidelines established by the Department of Environmental Health and Safety. |
| ☐Yes ☐No | As applicable, employees will be offered vaccination, banking of serum or standard body material, and HIV testing. Banked material will be used for detection of compounds or serum conversion in the event of exposure. |
| □Yes □No | Approval of this application is only for the biohazardous agents and procedures described herein. Any changes to the protocol (e.g., change of organisms, vectors, procedures, personnel, project location, etc.) must be approved by amendment prior to use or implementation. |

| PI Name: |
|----------|
| |

18. Project Summary Section.

Please provide a brief overview of the proposed research containing sufficient information to ensure adequate review of the protocol to determine compliance with Wright State University's Biosafety Program and local, state, and federal regulations. DO NOT cut and past the specific aims section from a grant application.

- a. Purpose of research (brief);
- b. Assessment of risk to personnel working with the biological agent;
- c. An outline of the procedures and techniques employed;
- d. Description of the safe practices, equipment, and facilities used to protect personnel;
- e. Describe any specific methods of inactivation or disposal of the agent not mentioned above.

Attach additional sheets as necessary.